"In an initial commentary post H1 result release earlier today, UBS analysts mention a "strong beat", primarily driven by USA margin.
The outlook remains for softening demand in A&NZ (though the margin 'beat' here as well).The broker lauds management's ability to keep costs in check, which is considered the key standout feature of today's result. Top line is in line.
In light of ongoing challenges ahead, the broker sees the multiple as too elevated. Sell rating. Target $16.60"
- Forums
- ASX - By Stock
- REH
- Ann: Half Yearly Report and Accounts
Ann: Half Yearly Report and Accounts, page-10
Featured News
Add REH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$24.50 |
Change
0.440(1.83%) |
Mkt cap ! $15.82B |
Open | High | Low | Value | Volume |
$24.04 | $24.59 | $23.94 | $10.95M | 448.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7989 | $24.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$24.66 | 2627 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 618 | 24.230 |
1 | 21 | 23.790 |
1 | 210 | 23.700 |
1 | 200 | 23.460 |
2 | 67 | 23.400 |
Price($) | Vol. | No. |
---|---|---|
25.140 | 105 | 1 |
25.850 | 812 | 1 |
26.000 | 2284 | 3 |
26.240 | 200 | 1 |
26.950 | 3937 | 3 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
REH (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online